Mainz Biomed NV’s eAArly DETECT Study Reports 97% Sensitivity, Stock Still Dips
Mainz Biomed NV, a leading molecular genetics diagnostic company specializing in early cancer detection, made a groundbreaking announcement today, revealing topline results from its eAArly
